Welcome to our dedicated page for eXoZymes SEC filings (Ticker: EXOZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The eXoZymes Inc. (EXOZ) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. eXoZymes is a Nevada corporation with common stock listed on the Nasdaq Capital Market under the ticker EXOZ, as noted in its Form 8-K reports. Through these filings, the company furnishes information about material events related to its AI-enhanced, cell-free biomanufacturing platform and associated programs.
Recent Form 8-K filings have attached press releases and investor presentations that describe key developments in eXoZymes’ business. These include a press release on the 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production using its exozyme-based platform, with reported conversion levels of over 99% from feedstock to product, and investor materials related to its NCTx business. Other 8-Ks have provided updated investor presentations that outline the company’s focus on exozymes, cell-free biomanufacturing, and highly valuable natural product molecules.
On Stock Titan, investors can review these EXOZ filings alongside AI-powered summaries that explain the context and main points of each document. Real-time updates from the SEC’s EDGAR system help surface new 8-Ks and other forms as they are filed, while AI-generated overviews aim to make complex disclosures easier to understand.
For those tracking eXoZymes, the filings page is a way to see how the company formally reports material events such as technical milestones, investor communications, and business updates tied to its biomanufacturing platform. Users can also look for additional forms, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 when they are available, with AI tools helping to highlight important information within these documents.
Exozymes Inc. filed a Form 8-K to inform investors that it issued a press release dated January 29, 2026. The release announces the advancing commercial readiness of the company’s initial NCT pilot run, indicating progress toward moving this early-stage initiative closer to potential commercial use.
eXoZymes Inc. has put in place a shelf registration to offer up to
The company states that, unless specified otherwise in a supplement, net proceeds will be used for general corporate purposes and working capital, which may include capital spending, research and development, regulatory and clinical trial costs, technology or asset acquisitions and business expansion. eXoZymes’ common stock trades on the Nasdaq Capital Market under the symbol EXOZ, and as of January 23, 2026, there were 8,400,258 shares of common stock issued, with a closing price of
eXoZymes Inc. is registering up to $50,000,000 of securities under a new shelf registration statement. The mixed shelf allows the company to issue, from time to time, common stock, preferred stock, debt securities, warrants, subscription rights and units in one or more future offerings, with specific terms to be set in accompanying prospectus supplements.
The company’s common stock trades on the Nasdaq Capital Market under the symbol EXOZ, with a closing price of $10.77 per share on January 15, 2026, and 8,400,258 shares of common stock were issued as of January 16, 2026. eXoZymes intends to use net proceeds primarily for working capital and general corporate purposes, including research and development, regulatory activities, clinical trials, capital expenditures, and potential technology acquisitions or business expansions, which may result in dilution to existing stockholders.
Exozymes Inc. filed a Form S-8 registration statement to register securities for its 2025 Performance Equity Plan. The filing states that it will become effective upon submission under Rule 462.
Exozymes incorporates by reference its Form 10-K for the year ended December 31, 2024, its 2025 quarterly and current reports, its proxy statement, and the description of its common stock. As a Nevada corporation, it describes indemnification and limitation of liability protections for directors and officers, supported by directors’ and officers’ liability insurance and separate indemnification agreements.
ExoZymes Inc. filed a current report to announce that it has issued a press release about scaling up production of NCT using its exozymes technology. The company classifies this as an "Other Event," highlighting operational progress rather than a financial update or major transaction. The press release, dated December 11, 2025, is furnished as an exhibit to the report, indicating the company wants investors informed about this step in its production capabilities while remaining listed on the Nasdaq Capital Market under the symbol EXOZ.
eXoZymes Inc. filed an 8-K announcing an updated Investor Presentation as of November 13, 2025. The update, tied to its NCTx business, is furnished under Item 8.01 (Other Events) and provided as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Capital Market under the symbol EXOZ. The report lists the company’s principal office at 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.
eXoZymes Inc. (EXOZ) filed its Q3 2025 10-Q, reporting continued operating losses and a going concern warning. The company posted a net loss of $2,286,991 for the quarter and $6,503,698 for the nine-month period. Basic and diluted EPS were $(0.27) for the quarter and $(0.78) year-to-date.
Cash and cash equivalents were $5,098,687 as of September 30, 2025, down from $9,719,310 at year-end, reflecting operating cash outflows of $4,528,240 for the nine months. Operating costs rose to $7,020,981 year-to-date, driven by higher general and administrative expenses of $4,426,216 and research and development costs, net of grants, of $2,594,765. Grants offset R&D by $1,120,907 year-to-date, including $256,474 in Q3.
The company recorded a discrete income tax receivable of $105,826 in Q3. Management states there is substantial doubt about the company’s ability to continue as a going concern given its pre-revenue status and anticipated funding shortfalls. Shares outstanding were 8,387,250 as of November 13, 2025.
eXoZymes Inc. filed a current report to make public an updated Investor Presentation as of September 30, 2025. The company, which is listed on the Nasdaq Capital Market under the symbol EXOZ, is using this report to formally furnish the latest version of its presentation to investors and analysts.
The presentation is included as Exhibit 99.1 and is described as an Investor Presentation of eXoZymes Inc. as of September 30, 2025. No new financial results, transactions, or other specific operating updates are detailed in the text of this report itself.